Nifty Pharma rises 1% as some Indian drugs get US tariff relief
In short
Nifty Pharma rose 1% after news that some Indian speciality medicines may get zero duty in the US.
This could help Indian drugmakers that sell to the US. The exact drugs and the size of the benefit are not stated in the available reporting.
What the reporting says
Nifty Pharma rose 1% as select Indian speciality medicines were reported to qualify for zero duty in the US. The publisher-supplied summary says this offers relief to Indian drugmakers with exposure to the US market. The exact products covered, the tariff schedule, and the size of the benefit are not stated in the available reporting.
Why it matters
Nifty Pharma gained 1% after a report that qualifying speciality medicines from India will be eligible for zero duty in the US. That could ease pressure on Indian drugmakers with US sales exposure. The reporting does not say which medicines qualify, how broad the exemption is, or whether the tariff relief is already in force.